Results 41 to 50 of about 1,300 (156)

A Systematic Review and Meta-analysis of Efficacy and Safety of Mavacamten for the Treatment of Hypertrophic Cardiomyopathy

Reviews in Cardiovascular Medicine
Background: Hypertrophic cardiomyopathy (HCM) is a common hereditary cardiomyopathy. Mavacamten, a first-in-class cardiac myosin inhibitor, is considered to be a specific drug for the treatment of HCM.
Li Zheng, Xiaotong Gu, Yumiao Chen, Deping Liu   +3 more
doaj   +1 more source

Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Clopidogrel is an antiplatelet agent widely utilized in cardiology. It is a prodrug activated in the liver by the cytochrome P450 isoform CYP2C19. Variability in the CYPC2C19 gene influences the activation and efficacy of clopidogrel. This is covered in guidelines from the Clinical Pharmacogenetics Implementation Consortium, the Dutch ...
Cinzia Dello Russo, Luigi Venetucci, Abisope Akintola, Dimitri Gagliardi, Ronnie Ramlogan, Munir Pirmohamed   +5 more
wiley   +1 more source

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy

British Journal of Pharmacology, Volume 183, Issue 5, Page 1122-1139, March 2026.
Abstract Background and Purpose Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM). Despite its recent approval for clinical use, the transcriptional and functional impacts of MAVA remain not well understood.
Elisa Kiselev, Wilson Agyapong, Bjarne Jürgens, Elisa Mohr, Shambhabi Chatterjee, Hannah J. Hunkler, Jawad Salman, Giuseppe Cipriano, Marco Bentele, Junqing Liu, Jonas Specht, Kaja S. Menge, Florian J. G. Waleczek, Jonas A. Haas, Anselm A. Derda, Kristina Sonnenschein, Anika Gietz, Susanne Neumüller, Angelika Pfanne, Oliver Beetz, Michael Pflaum, Bettina Wiegmann, Yiangos Psaras, Christopher Toepfer, Robert Zweigerdt, Ante Radocaj, Theresia Kraft, Andre Zeug, Evgeni Ponimaskin, Wilhelm Korte, Alexander Horke, Arjang Ruhparwar, Maximilian Fuchs, Ke Xiao, Christian Bär, Natalie Weber, Thomas Thum   +36 more
wiley   +1 more source

Clinical Evaluation of Drug–Drug Interactions With Aficamten

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Aficamten is a next‐in‐class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). A comprehensive drug–drug interaction (DDI) evaluation of aficamten was achieved through two phase 1 studies in ...
Neha Maharao, Donghong Xu, Punag Divanji, Tyrell J. Simkins, Jianlin Li, Camelia Dumitrescu, Priyanka Solanki, Adrienne Griffith, Stephen B. Heitner, Stuart Kupfer, Polina German, Justin D. Lutz   +11 more
wiley   +1 more source

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Mavacamten is the first and only cardiac myosin inhibitor approved in 5 continents for the treatment of adults with symptomatic New York Heart Association class II and III obstructive hypertrophic cardiomyopathy.
Anjali T. Owens, Milind Desai, Matthew T. Wheeler, Anna Rodonski, Samira Merali, Amy J. Sehnert, Sara Saberi   +6 more
doaj   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 329-347, February 2026.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source

One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy

Frontiers in Cardiovascular Medicine
Mavacamten is a first-in-class cardiac myosin ATPase inhibitor, approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology (oHCM).
Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Emily L. Chu, Emily E. Keamy-Minor, Ishan Dhananjay Paranjpe, Wilson L. Tang, Jack W. O’Sullivan, Jack W. O’Sullivan, Jack W. O’Sullivan, Yaanik B. Desai, Yaanik B. Desai, Michael B. Liu, Michael B. Liu, Elise Munsey, Kimberly Hecker, Isabella Cuenco, Beth Kao, Ellen Bacolor, Colleen Bonnett, Andrea Linder, Kathleen Lacar, Nancy Robles, Cindy Lamendola, Allysonne Smith, Joshua W. Knowles, Joshua W. Knowles, Joshua W. Knowles, Joshua W. Knowles, Marco V. Perez, Marco V. Perez, Marco V. Perez, Marco V. Perez, Masataka Kawana, Masataka Kawana, Masataka Kawana, Karim I. Sallam, Karim I. Sallam, Karim I. Sallam, Chad S. Weldy, Chad S. Weldy, Chad S. Weldy, Matthew T. Wheeler, Matthew T. Wheeler, Matthew T. Wheeler, Matthew T. Wheeler, Victoria N. Parikh, Victoria N. Parikh, Victoria N. Parikh, Victoria N. Parikh, Heidi Salisbury, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, the Stanford Center for Inherited Cardiovascular Disease, Karim I Sallam, Masataka Kawana, Chad S Weldy, Marco Perez, Joshua W Knowles, Jason Tso, Cindy Lamendola, Allysonne Smith, Nancy Robles, Colleen Bonnett, Ellen Bacolor, Kimberly Hecker, Isabella Cuenco, Beth Kao, Elise Munsey, Andrea Linder, Kathleen Lacar, Julia Platt, Chloe Reuter, Tia Moscarello, Ryan Murtha, Jennifer Kohler, Hannah Ison, Mitchel Pariani, Anusha Klinder, Priya Nair, Jennifer Marino, Andrea Linder, Ruchi Patel, Matthew T Wheeler, Euan A Ashley, Victoria N Parikh   +92 more
doaj   +1 more source

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 30-32, January 2026.
In this issue of CPT, Malavé et al. deliver a comprehensive reassessment of CYP2C19 inhibitor classifications through a systematic review of clinical drug–drug interaction (DDI) studies. While their findings bring clarity to specific discrepancies, this commentary explores the origins of such inconsistencies, particularly focusing on methodological ...
Janne T. Backman
wiley   +1 more source

Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The phase 2 PIONEER‐HCM (Phase 2 Open‐label Pilot Study Evaluating Mavacamten in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction) study showed that mavacamten improved left ventricular ...
Ahmad Masri, Steven J. Lester, John C. Stendahl, Sheila M. Hegde, Amy J. Sehnert, Ganesh Balaratnam, Ashish Shah, Shawna Fox, Andrew Wang   +8 more
doaj   +1 more source